GlassScriptPhysician profile
Ismail Ozcan
NPI 1932271509
$2,766.50
in general payments reported to CMS, 2019-2025
24 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $61.00 · 2021: $147 · 2022: $533 · 2023: $348 · 2024: $885 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $348.50 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Medtronic, INC. | $308.31 | 2022-2024 | Closurefast, Venaseal |
| Boston Scientific Corporation | $297.63 | 2019-2023 | Apollo Esg System |
| Novo Nordisk INC | $281.10 | 2021-2025 | |
| Allergan, INC. | $232.44 | 2019-2022 | |
| Abbvie INC. | $225.28 | 2022-2024 | |
| Galderma Laboratories, L.P. | $211.67 | 2019 | |
| Lilly USA, LLC | $207.11 | 2022-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $117.39 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Depuy Synthes Sales INC. | $82.01 | 2024 | Orthovisc, Monovisc |
| Pfizer INC. | $65.29 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $64.60 | 2020-2022 | |
| Lundbeck LLC | $51.09 | 2024 | Vyepti, Rexulti |
| Biomarin Pharmaceutical INC. | $47.45 | 2024 | Voxzogo 1.2mg |
| Dexcom, INC. | $45.08 | 2022-2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $41.02 | 2025 | Spinosad, Natroba |
| Shield Therapeutics INC | $24.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.08 | 2025 | |
| Smith+Nephew, INC. | $16.82 | 2024 | Collagenase Santyl |
| Exact Sciences Corporation | $16.07 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $13.28 | 2025 | Voquezna |
| Tactile Systems Technology INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismail Ozcan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.